Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Sponsor: FORUM Pharmaceuticals Inc
This PHASE3 trial investigates Impaired Cognition and Schizophrenia and is currently completed. FORUM Pharmaceuticals Inc leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FORUM Pharmaceuticals Inc
- NeuroCog Trials, Inc.
- Syneos Health
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Austin, United States , Ban, Italy , Banfield, Argentina , Barl, Italy , Barranquilla, Colombia , Beachwood, United States , Bellevue, United States , Belo Horizonte, Brazil , Bełchatów, Poland and 95 more locations